170 related articles for article (PubMed ID: 19386610)
1. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study.
Haugeberg G; Conaghan PG; Quinn M; Emery P
Ann Rheum Dis; 2009 Dec; 68(12):1898-901. PubMed ID: 19386610
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis.
Vis M; Havaardsholm EA; Haugeberg G; Uhlig T; Voskuyl AE; van de Stadt RJ; Dijkmans BA; Woolf AD; Kvien TK; Lems WF
Ann Rheum Dis; 2006 Nov; 65(11):1495-9. PubMed ID: 16606653
[TBL] [Abstract][Full Text] [Related]
3. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?
van der Goes MC; Jacobs JW; Jurgens MS; Bakker MF; van der Veen MJ; van der Werf JH; Welsing PM; Bijlsma JW
Osteoporos Int; 2013 Apr; 24(4):1429-36. PubMed ID: 23011680
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
Wijbrandts CA; Klaasen R; Dijkgraaf MG; Gerlag DM; van Eck-Smit BL; Tak PP
Ann Rheum Dis; 2009 Mar; 68(3):373-6. PubMed ID: 18408246
[TBL] [Abstract][Full Text] [Related]
5. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis.
Buckley LM; Leib ES; Cartularo KS; Vacek PM; Cooper SM
J Rheumatol; 1997 Aug; 24(8):1489-94. PubMed ID: 9263140
[TBL] [Abstract][Full Text] [Related]
6. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
7. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
[TBL] [Abstract][Full Text] [Related]
8. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis.
Güler-Yüksel M; Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; van Groenendael JH; Mallée C; de Bois MH; Breedveld FC; Dijkmans BA; Lems WF
Ann Rheum Dis; 2009 Mar; 68(3):330-6. PubMed ID: 18375540
[TBL] [Abstract][Full Text] [Related]
9. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
Jensen TW; Hansen MS; Hørslev-Petersen K; Hyldstrup L; Abrahamsen B; Langdahl B; Zerahn B; Pødenphant J; Stengaard-Petersen K; Junker P; Østergaard M; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Lindegaard H; Jurik AG; Vestergaard A; Hetland ML;
Ann Rheum Dis; 2014 Jun; 73(6):1123-9. PubMed ID: 23661492
[TBL] [Abstract][Full Text] [Related]
10. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab.
Marotte H; Pallot-Prades B; Grange L; Gaudin P; Alexandre C; Miossec P
Arthritis Res Ther; 2007; 9(3):R61. PubMed ID: 17597527
[TBL] [Abstract][Full Text] [Related]
11. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
12. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Maini R; St Clair EW; Breedveld F; Furst D; Kalden J; Weisman M; Smolen J; Emery P; Harriman G; Feldmann M; Lipsky P
Lancet; 1999 Dec; 354(9194):1932-9. PubMed ID: 10622295
[TBL] [Abstract][Full Text] [Related]
13. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Conaghan PG; Østergaard M; Bowes MA; Wu C; Fuerst T; van der Heijde D; Irazoque-Palazuelos F; Soto-Raices O; Hrycaj P; Xie Z; Zhang R; Wyman BT; Bradley JD; Soma K; Wilkinson B
Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis.
Antoni C; Kalden JR
Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S73-7. PubMed ID: 10589362
[TBL] [Abstract][Full Text] [Related]
15. Infliximab in active early rheumatoid arthritis.
Breedveld FC; Emery P; Keystone E; Patel K; Furst DE; Kalden JR; St Clair EW; Weisman M; Smolen J; Lipsky PE; Maini RN
Ann Rheum Dis; 2004 Feb; 63(2):149-55. PubMed ID: 14722203
[TBL] [Abstract][Full Text] [Related]
16. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing.
Smolen JS; van der Heijde DM; Aletaha D; Xu S; Han J; Baker D; St Clair EW
Ann Rheum Dis; 2009 Oct; 68(10):1535-40. PubMed ID: 18957487
[TBL] [Abstract][Full Text] [Related]
17. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
Visvanathan S; Wagner C; Smolen J; St Clair EW; Hegedus R; Baker D; Keenan G
Arthritis Rheum; 2006 Sep; 54(9):2840-4. PubMed ID: 16948115
[TBL] [Abstract][Full Text] [Related]
18. [Are there any positive effects of TNF-alpha blockers on bone metabolism?].
Seriolo B; Paolino S; Sulli A; Cutolo M
Reumatismo; 2006; 58(3):199-205. PubMed ID: 17013436
[TBL] [Abstract][Full Text] [Related]
19. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients.
Østergaard M; Emery P; Conaghan PG; Fleischmann R; Hsia EC; Xu W; Rahman MU
Arthritis Rheum; 2011 Dec; 63(12):3712-22. PubMed ID: 22127693
[TBL] [Abstract][Full Text] [Related]
20. Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial.
Ørnbjerg LM; Østergaard M; Jensen T; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Hetland ML; ; Slot O; Nielsen LK; Skjødt H; Majgaard O; Lorenzen T; Horn HC; Kowalski M; Johansen IL; Pedersen PM; Manilo N; Bliddal H
Clin Rheumatol; 2017 Apr; 36(4):781-789. PubMed ID: 27921185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
